• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

CAR在肺动脉高压微球模型中选择性增强法舒地尔的肺血管舒张作用。

CAR Selectively Enhances the Pulmonary Vasodilatory Effect of Fasudil in a Microsphere Model of Pulmonary Hypertension.

作者信息

Rothman Abraham, Restrepo Humberto, Evans William N, Sarukhanov Valeri, Mann David

机构信息

Children's Heart Center, Nevada 3131 La Canada, Suite 230, Las Vegas, NV 89169, USA.

Department of Pediatrics, University of Nevada Las Vegas, School of Medicine, 2040 W Charleston Blvd Ste. 402, Las Vegas, NV 89109, USA.

出版信息

Open Respir Med J. 2023 Apr 27;17:e187430642303160. doi: 10.2174/18743064-v17-e230404-2022-19. eCollection 2023.

DOI:10.2174/18743064-v17-e230404-2022-19
PMID:37916136
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10351346/
Abstract

BACKGROUND

Despite the approval of several medications for pulmonary hypertension, morbidity and mortality are unacceptably high. Systemic hypotension may limit the use of pulmonary hypertension medications.

OBJECTIVES

This study aimed to assess whether the homing peptide CAR (CARSKNKDC) improves the vasodilatory selectivity of fasudil in the pulmonary circulation or systemic circulation in a porcine pulmonary hypertension model.

MATERIALS AND METHODS

Pulmonary hypertension (to approximately 2/3-3/4 systemic pressure levels) was induced by chronic and acute administration of microspheres in 3 micro Yucatan pigs (mean weight 19.9 kg, mean age 4.3 months). Fasudil (0.3 mg/kg) was administered without and with CAR (1.5 mg/kg), and the effect on aortic (Ao) and right ventricular (RV) pressure was recorded with indwelling catheters.

RESULTS

Immediately after fasudil administration, there was a decrease in Ao pressure followed by prompt recovery to baseline. The RV pressure decrease was progressive and sustained. Fasudil alone resulted in a 12% decrease in RV pressure, whereas co-administration of CAR with fasudil resulted in a 22% decrease in RV pressure (p < 0.0001). Fasudil alone caused an average decrease of 34% in the RV/Ao pressure ratio, and fasudil + CAR caused an average decrease of 40% in the RV/Ao pressure ratio (p < 0.0001).

CONCLUSION

The homing peptide CAR selectively enhanced the acute vasodilatory effects of fasudil on the pulmonary vascular bed in a porcine experimental model of pulmonary hypertension.

摘要

背景

尽管已有多种治疗肺动脉高压的药物获批,但发病率和死亡率仍高得令人无法接受。系统性低血压可能会限制肺动脉高压药物的使用。

目的

本研究旨在评估归巢肽CAR(CARSKNKDC)是否能改善法舒地尔在猪肺动脉高压模型中对肺循环或体循环的血管舒张选择性。

材料与方法

通过对3只微型尤卡坦猪(平均体重19.9 kg,平均年龄4.3个月)慢性和急性给予微球诱导肺动脉高压(至约2/3 - 3/4体循环压力水平)。分别在未给予和给予CAR(1.5 mg/kg)的情况下给予法舒地尔(0.3 mg/kg),并通过留置导管记录对主动脉(Ao)和右心室(RV)压力的影响。

结果

给予法舒地尔后,Ao压力立即下降,随后迅速恢复至基线。RV压力下降是渐进性且持续的。单独使用法舒地尔导致RV压力下降12%,而CAR与法舒地尔联合使用导致RV压力下降22%(p < 0.0001)。单独使用法舒地尔使RV/Ao压力比值平均下降34%,法舒地尔 + CAR使RV/Ao压力比值平均下降40%(p < 0.0001)。

结论

在猪肺动脉高压实验模型中,归巢肽CAR选择性增强了法舒地尔对肺血管床的急性血管舒张作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e458/10351346/8061366c096f/TORMJ-17-E187430642303160_F3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e458/10351346/b9a813727ab9/TORMJ-17-E187430642303160_F1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e458/10351346/852e642fbbec/TORMJ-17-E187430642303160_F2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e458/10351346/8061366c096f/TORMJ-17-E187430642303160_F3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e458/10351346/b9a813727ab9/TORMJ-17-E187430642303160_F1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e458/10351346/852e642fbbec/TORMJ-17-E187430642303160_F2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e458/10351346/8061366c096f/TORMJ-17-E187430642303160_F3.jpg

相似文献

1
CAR Selectively Enhances the Pulmonary Vasodilatory Effect of Fasudil in a Microsphere Model of Pulmonary Hypertension.CAR在肺动脉高压微球模型中选择性增强法舒地尔的肺血管舒张作用。
Open Respir Med J. 2023 Apr 27;17:e187430642303160. doi: 10.2174/18743064-v17-e230404-2022-19. eCollection 2023.
2
Intratracheally Administered Peptide-Modified Lipid Admixture Containing Fasudil and/or DETA NONOate Ameliorates Various Pathologies of Pulmonary Arterial Hypertension.经气管内给予含法舒地尔和/或DETA NONOate的肽修饰脂质混合物可改善肺动脉高压的各种病理状况。
Pharmaceuticals (Basel). 2023 Nov 28;16(12):1656. doi: 10.3390/ph16121656.
3
Fasudil and DETA NONOate, Loaded in a Peptide-Modified Liposomal Carrier, Slow PAH Progression upon Pulmonary Delivery.载多肽修饰脂质体载体的法舒地尔和 DETA NONOate 经肺部给药可减缓肺动脉高压进展。
Mol Pharm. 2018 May 7;15(5):1755-1765. doi: 10.1021/acs.molpharmaceut.7b01003. Epub 2018 Mar 26.
4
A novel vascular homing peptide strategy to selectively enhance pulmonary drug efficacy in pulmonary arterial hypertension.一种新型血管归巢肽策略,可选择性增强肺动脉高压中的肺药物疗效。
Am J Pathol. 2014 Feb;184(2):369-75. doi: 10.1016/j.ajpath.2013.10.008. Epub 2014 Jan 6.
5
Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil.法舒地尔可降低野百合碱诱导的肺动脉高压:与波生坦和西地那非的比较。
Eur Respir J. 2010 Oct;36(4):800-7. doi: 10.1183/09031936.00130209. Epub 2010 Mar 29.
6
Peptide-coated liposomal fasudil enhances site specific vasodilation in pulmonary arterial hypertension.肽包被脂质体法舒地尔增强肺动脉高压中的位点特异性血管舒张。
Mol Pharm. 2014 Dec 1;11(12):4374-84. doi: 10.1021/mp500456k. Epub 2014 Nov 4.
7
Maxingxiongting mixture attenuates hypoxia pulmonary arterial hypertension to improve right ventricular hypertrophy by inhibiting the rho-kinase signaling pathway.脉胸通合剂通过抑制 Rho 激酶信号通路减轻低氧性肺动脉高压致右心室肥厚。
J Tradit Chin Med. 2020 Dec;40(6):992-998. doi: 10.19852/j.cnki.jtcm.2020.06.010.
8
Cell permeable peptide conjugated nanoerythrosomes of fasudil prolong pulmonary arterial vasodilation in PAH rats.法舒地尔的细胞穿透肽缀合纳米红细胞延长了PAH大鼠的肺动脉血管舒张作用。
Eur J Pharm Biopharm. 2014 Nov;88(3):1046-55. doi: 10.1016/j.ejpb.2014.10.012.
9
Peptide-micelle hybrids containing fasudil for targeted delivery to the pulmonary arteries and arterioles to treat pulmonary arterial hypertension.含有法舒地尔的肽-胶束杂化物,用于靶向递送至肺动脉和小动脉以治疗肺动脉高压。
J Pharm Sci. 2014 Nov;103(11):3743-3753. doi: 10.1002/jps.24193. Epub 2014 Sep 29.
10
Rosuvastatin intensifies the beneficial effects of rho-kinase inhibitor in reversal of monocrotaline-induced pulmonary hypertension.瑞舒伐他汀增强了Rho激酶抑制剂在逆转野百合碱诱导的肺动脉高压中的有益作用。
Arch Med Sci. 2016 Aug 1;12(4):898-905. doi: 10.5114/aoms.2015.49740. Epub 2015 May 22.

本文引用的文献

1
Pulmonary Hypertension.肺动脉高压
Med Clin North Am. 2019 May;103(3):413-423. doi: 10.1016/j.mcna.2018.12.002.
2
Pulmonary arterial hypertension: pathogenesis and clinical management.肺动脉高压:发病机制与临床管理
BMJ. 2018 Mar 14;360:j5492. doi: 10.1136/bmj.j5492.
3
Large Animal Model Efficacy Testing Is Needed Prior to Launch of a Stem Cell Clinical Trial: An Evidence-Lacking Conclusion Based on Conjecture.在开展干细胞临床试验之前需要进行大动物模型疗效测试:基于推测得出的缺乏证据的结论。
Circ Res. 2017 Aug 18;121(5):496-498. doi: 10.1161/CIRCRESAHA.117.311562.
4
Challenges in the development of chronic pulmonary hypertension models in large animals.大型动物慢性肺动脉高压模型开发中的挑战。
Pulm Circ. 2017 Feb 1;7(1):156-166. doi: 10.1086/690099. eCollection 2017 Mar.
5
Cocktail of Superoxide Dismutase and Fasudil Encapsulated in Targeted Liposomes Slows PAH Progression at a Reduced Dosing Frequency.包裹在靶向脂质体中的超氧化物歧化酶和法舒地尔鸡尾酒疗法以降低的给药频率减缓肺动脉高压进展。
Mol Pharm. 2017 Mar 6;14(3):830-841. doi: 10.1021/acs.molpharmaceut.6b01061. Epub 2017 Feb 17.
6
A global view of pulmonary hypertension.肺动脉高压的全球视野。
Lancet Respir Med. 2016 Apr;4(4):306-22. doi: 10.1016/S2213-2600(15)00543-3. Epub 2016 Mar 12.
7
Acute effects of Rho-kinase inhibitor fasudil on pulmonary arterial hypertension in patients with congenital heart defects.Rho激酶抑制剂法舒地尔对先天性心脏病患者肺动脉高压的急性影响。
Circ J. 2015;79(6):1342-8. doi: 10.1253/circj.CJ-14-1015. Epub 2015 Mar 23.
8
Acute hemodynamic response of infused fasudil in patients with pulmonary arterial hypertension: a randomized, controlled, crossover study.法舒地尔输注对肺动脉高压患者的急性血流动力学反应:一项随机、对照、交叉研究。
Int J Cardiol. 2014 Nov 15;177(1):61-5. doi: 10.1016/j.ijcard.2014.09.101. Epub 2014 Sep 28.
9
Cell permeable peptide conjugated nanoerythrosomes of fasudil prolong pulmonary arterial vasodilation in PAH rats.法舒地尔的细胞穿透肽缀合纳米红细胞延长了PAH大鼠的肺动脉血管舒张作用。
Eur J Pharm Biopharm. 2014 Nov;88(3):1046-55. doi: 10.1016/j.ejpb.2014.10.012.
10
Peptide-micelle hybrids containing fasudil for targeted delivery to the pulmonary arteries and arterioles to treat pulmonary arterial hypertension.含有法舒地尔的肽-胶束杂化物,用于靶向递送至肺动脉和小动脉以治疗肺动脉高压。
J Pharm Sci. 2014 Nov;103(11):3743-3753. doi: 10.1002/jps.24193. Epub 2014 Sep 29.